Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
15
pubmed:dateCreated
2011-8-1
pubmed:abstractText
Identification and reversal of treatment resistance mechanisms of clinically refractory tumor cells is critical for successful cancer therapy. Here we show that ATP-binding cassette member B5 (ABCB5) identifies therapy-refractory tumor cells in colorectal cancer patients following fluorouracil (5-FU)-based chemoradiation therapy and provide evidence for a functional role of ABCB5 in colorectal cancer 5-FU resistance. Examination of human colon and colorectal cancer specimens revealed ABCB5 to be expressed only on rare cells within healthy intestinal tissue, whereas clinical colorectal cancers exhibited substantially increased levels of ABCB5 expression. Analysis of successive, patient-matched biopsy specimens obtained prior to and following neoadjuvant 5-FU-based chemoradiation therapy in a series of colorectal cancer patients revealed markedly enhanced abundance of ABCB5-positive tumor cells when residual disease was detected. Consistent with this finding, the ABCB5-expressing tumor cell population was also treatment refractory and exhibited resistance to 5-FU-induced apoptosis in a colorectal cancer xenograft model of 5-FU monotherapy. Mechanistically, short hairpin RNA-mediated ABCB5 knockdown significantly inhibited tumorigenic xenograft growth and sensitized colorectal cancer cells to 5-FU-induced cell killing. Our results identify ABCB5 as a novel molecular marker of therapy-refractory tumor cells in colorectal cancer patients and point to a need for consistent eradication of ABCB5-positive resistant tumor cell populations for more effective colorectal cancer therapy.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1538-7445
pubmed:author
pubmed:issnType
Electronic
pubmed:day
1
pubmed:volume
71
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
5307-16
pubmed:meshHeading
pubmed-meshheading:21652540-Adenocarcinoma, pubmed-meshheading:21652540-Animals, pubmed-meshheading:21652540-Antimetabolites, Antineoplastic, pubmed-meshheading:21652540-Colorectal Neoplasms, pubmed-meshheading:21652540-Combined Modality Therapy, pubmed-meshheading:21652540-Drug Resistance, Neoplasm, pubmed-meshheading:21652540-Fluorouracil, pubmed-meshheading:21652540-Humans, pubmed-meshheading:21652540-Interleukin Receptor Common gamma Subunit, pubmed-meshheading:21652540-Mice, pubmed-meshheading:21652540-Mice, Inbred NOD, pubmed-meshheading:21652540-Mice, SCID, pubmed-meshheading:21652540-Neoadjuvant Therapy, pubmed-meshheading:21652540-Neoplasm Proteins, pubmed-meshheading:21652540-P-Glycoprotein, pubmed-meshheading:21652540-RNA, Small Interfering, pubmed-meshheading:21652540-Tumor Markers, Biological, pubmed-meshheading:21652540-Xenograft Model Antitumor Assays
pubmed:year
2011
pubmed:articleTitle
ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients.
pubmed:affiliation
Transplantation Research Center, Children's Hospital, Boston, MA, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, N.I.H., Extramural